Louise C. Strong, M.D.
Department of Genetics, Division of SVP Chief Academic Officer
Present Title & Affiliation
Primary Appointment
Professor, Department of Genetics, Division of Basic Science Research, UTMDACC, Houston, TX
Professor, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Professor of Cancer Genetics, Department of Breast Medical Oncology, Division of Cancer Medicine, UTMDACC, Houston, TX
Research Interests
Human cancer genetics Genetic epidemiology
The program involves the study of genetic etiology of human cancer using genetic epidemiologic approach to identify the most likely etiologic model(s) to account for the distribution of tumors in kindreds, and to test for genetic/etiologic heterogeneity. We then identify families in which a genetic etiology seems likely for collaborative study using cytogenetic, biochemical and molecular markers to localize the gene. We are further investigating the role of radiation, chemotherapy and host predisposing factors in the risk of subsequent tumors in childhood cancer survivors and in the reproductive outcomes in childhood cancer survivors.
A tutorial in this laboratory would include introduction to field work of data collection by interview, analytic techniques of genetic epidemiology and interpretation of laboratory findings from the collaborative laboratory studies.
View a complete list of Dr. Strong's publications .
Visit Dr. Strong’s Li Fraumeni Syndrome Study Group website.
Education & Training
Degree-Granting Education
| 1970 | University of Texas Medical Branch, Galveston, TX, USA, MD, Medicine |
| 1966 | University of Texas, Austin, TX, USA, BA, Mathematics |
Postgraduate Training
| 1970-1972 | Postdoctoral Fellowship, Texas Research Institute of Mental Sciences and The University of Texas Graduate School of Biomedical Sciences, Houston, TX |
Selected Publications
Peer-Reviewed Articles
- Palculict TB, Ruteshouser EC, Fan Y, Wang W, Strong L, Huff V. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumor using whole genome sequencing. J Med Genet 53(6):385-8, 2016. e-Pub 2015. PMID: 26566882.
- Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AT, Strong LC, Shaw K, Lu K, Qi Y, Lara-Guerra H, Litton J, Arun B, Zhao H, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies D, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology 27(5):795-800, 2016. PMID: 26787237.
- Malkin D, Garber JE, Strong LC, Friend SH. CANCER. The cancer predisposition revolution. Science 352(6289):1052-3, 2016. PMID: 27230363.
- Henderson TO, Moskowitz CS, Chou JF, Bradbury AR, Neglia JP, Dang CT, Onel K, Novetsky Friedman D, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring WM, Robison LL, Armstrong GT, Diller LR, Oeffinger KC. Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 34(9):910-918, 2016. e-Pub 2015. PMID: 26700127.
- Yang XR, Killian JK, Hammond S, Burke LS, Bennett H, Wang Y, Davis SR, Strong LC, Neglia J, Stovall M, Weathers RE, Robison LL, Bhatia S, Mabuchi K, Inskip PD, Meltzer P. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays. PLoS One 10(3):e0116078, 2015. e-Pub 2015. PMID: 25764003.
- Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun 5:3856, 2014. e-Pub 2014. PMID: 24920014.
- Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM. Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Res Treat 145(1):233-43, 2014. e-Pub 2014. PMID: 24696430.
- Gramatges MM, Liu Q, Yasui Y, Okcu MF, Neglia JP, Strong LC, Armstrong GT, Robison LL, Bhatia S. Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Clin Cancer Res 20(4):904-11, 2014. e-Pub 2013. PMID: 24277454.
- Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong LC, McGillivray B, Asrat M-J, Davidorf FH, Abdel-Rahman MH. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome. Genes Chromosomes Cancer 53(2):177–182, 2014. e-Pub 2013. PMID: 24243779.
- Powell BC, Jiang L, Muzny DM, Trevino L, Dreyer Z, Strong LC, Wheeler DA,. Gibbs RA, Plon SE. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 60(6):E1-3153, 2013. PMID: 23255406.
- Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Hum Genet 130(6):789-94, 2011. e-Pub 2011. PMID: 21688173.
- Wu, CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Shete S, Amos CI, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 129(6):663-73, 2011. e-Pub 2011. PMID: 21305319.
- Fang, S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson C, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in carriers of TP53 germline mutations. PLoS ONE 5(5):e10813, 2010. PMID: 20520810.
- Wu CC, Strong LC, Shete S.. Effects of measured susceptibility genes on cancer risk in family studies. Hum Genet 127(3):349-357, 2010. PMID: 20039063.
Letters to the Editor
- Leroy B, Strong LC, Soussi T. Revised guidelines for screening of TP53 gene mutations. Nature Rev Clin Oncol.